Compare NICE Ltd (NICE) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NICE Ltd vs Natera Inc. Common Stock — how do they compare? NICE Ltd trades at $110.41 (market cap $6.90B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 8.3× NICE Ltd's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, NICE Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NICE Ltd for 16 Days and Natera Inc. Common Stock for 0 Days on average.
| NICE | NTRA | |
|---|---|---|
Market Cap | $6.90B | $57.03B |
Volume | 665,954 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $136.90 | $425.64 |
52-Week Low | $83.15 | $179.42 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $6.63B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NICE stock trades at $114.95, down 0.08% on the day, with a bullish technical signal from moving averages and key support at $113. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.70 exceeding the $2.63 estimate. Revenue reached $2.95 billion in 2025, though net income is projected to decline to $425 million in 2026. Analyst consensus is a Buy with a $124.20 price target, and recent news highlights leadership in AI-driven contact center platforms.
The outlook for NICE is positive, driven by AI revenue growth and a low valuation, but investors face risks from margin compression due to heavy AI investments and competitive pressures. The stock's current price offers a potential 8% upside to the consensus target, supported by institutional buying interest and solid cash flow generation.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
